Welcome to our dedicated page for 21Shares Sui ETF SEC filings (Ticker: TSUI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on 21Shares Sui ETF's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into 21Shares Sui ETF's regulatory disclosures and financial reporting.
21Shares Sui ETF filed a prospectus supplement to include a Current Report on Form 8-K reporting that the Sponsor terminated its licensing agreement with CF Benchmarks Ltd., effective August 31, 2026.
The supplement states the Sponsor provided notice on June 30, 2026 and intends to enter a new licensing agreement with FTSE International Limited on or about August 24, 2026 to license FTSE index data for use in valuing and supporting the Trust.
21Shares Sui ETF is terminating its current pricing benchmark agreement with CF Benchmarks, effective August 31, 2026. The CME CF Sui — Dollar Reference Rate — New York Variant is presently used to value the ETF’s shares and calculate its net asset value each day.
The sponsor plans to enter a new licensing agreement with FTSE International Limited on or about August 24, 2026, under which FTSE will supply digital asset index data for developing, maintaining, and marketing the fund. Both the current and planned FTSE licenses feature initial one-year terms with automatic one-year renewals unless terminated.
21Shares Sui ETF filed its Quarterly Report on Form 10-Q and a prospectus supplement dated May 15, 2026 to include that Report. The Report discloses unaudited March 31, 2026 financials: net assets $15,092,444, NAV per share $17.55, and 790,000 shares outstanding as of May 11, 2026. The period from November 18, 2025 (initial seeding) through March 31, 2026 shows a net decrease in net assets of $(8,612,768) largely driven by an unrealized depreciation on its SUI holdings of $(8,365,012). The Trust held 17,213,810.1127 SUI tokens (fair value $15,093,069) and reported staking income of $22,491 for the period, net of a Sponsor Fee and Staking Fee. The filing also describes staking mechanics, Sponsor fee arrangements (0.30% annual Sponsor Fee) and the Sui Foundation one-year lock-up on 1,000,000 Shares.
21Shares Sui ETF reports its first full quarter of operations, showing how closely it tracks the SUI token. Net assets were $15,092,444 with 860,000 shares outstanding at March 31, 2026, giving a NAV per share of $17.55.
Over the quarter, NAV per share fell from $27.84 to $17.55, a total return of -36.96%, driven by a 36.69% drop in SUI’s price. Despite this, total NAV rose as the Trust issued 380,000 new shares and redeemed 20,000.
The Trust held 17,213,810.1127 SUI worth $15,093,069 and had 97.69% of its SUI staked at quarter-end, generating $22,491 of staking rewards. Expenses remained limited to a 0.30% annual Sponsor Fee and a Staking Fee of $5,623, with no debt and no material legal proceedings disclosed.